The cathepsin-S/protease-activated receptor-(PAR)-2 axis drives chronic allograft vasculopathy and is a molecular target for therapeutic intervention

Rana, 2015, Survival benefit of solid-organ transplant in the United States, JAMA Surg., 150, 252, 10.1001/jamasurg.2014.2038 Lee, 2018, Cardiac allograft vasculopathy: a review, Catheter. Cardiovasc. Interv., 92, E527, 10.1002/ccd.27893 Rana, 2019, Outcomes in solid-organ transplantation: success and stagnation, Tex. Heart Inst. J., 46, 75, 10.14503/THIJ-18-6749 Pober, 2014, Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy, Arterioscler. Thromb. Vasc. Biol., 34, 1609, 10.1161/ATVBAHA.114.302818 Kitchens, 2007, Macrophage depletion suppresses cardiac allograft vasculopathy in mice, Am. J. Transplant., 7, 2675, 10.1111/j.1600-6143.2007.01997.x Uehara, 2005, NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts, J. Immunol., 175, 3424, 10.4049/jimmunol.175.5.3424 Weenink, 1997, Antigen presentation by MHC class II molecules, Immunol. Cell Biol., 75, 69, 10.1038/icb.1997.11 Roche, 1991, Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules, Proc. Natl. Acad. Sci. U. S. A., 88, 3150, 10.1073/pnas.88.8.3150 Saegusa, 2002, Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity, J. Clin. Invest., 110, 361, 10.1172/JCI0214682 Baugh, 2011, Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity, J. Autoimmun., 36, 201, 10.1016/j.jaut.2011.01.003 Riese, 1998, Cathepsin S activity regulates antigen presentation and immunity, J. Clin. Investig., 101, 2351, 10.1172/JCI1158 Tato, 2017, Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury, Sci. Rep., 7, 2775, 10.1038/s41598-017-01894-y Rupanagudi, 2015, Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming, Ann. Rheum. Dis., 74, 452, 10.1136/annrheumdis-2013-203717 Sukhova, 1998, Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells, J. Clin. Investig., 102, 576, 10.1172/JCI181 Sukhova, 2003, Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice, J. Clin. Investig., 111, 897, 10.1172/JCI200314915 Rodgers, 2006, Destabilizing role of cathepsin S in murine atherosclerotic plaques, Arterioscler. Thromb. Vasc. Biol., 26, 851, 10.1161/01.ATV.0000203526.75772.4b Tennant, 2008, PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse, Atherosclerosis, 198, 57, 10.1016/j.atherosclerosis.2007.09.043 Kumar Vr, 2016, Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications, J. Am. Soc. Nephrol., 27, 1635, 10.1681/ASN.2015020208 Vergnolle, 1999, Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo, J. Immunol. (Baltimore, Md. 1950), 163, 5064, 10.4049/jimmunol.163.9.5064 Ryll, 2019, Murine cervical aortic transplantation model using a modified non-suture cuff technique, J. Vis. Exp., 153 Theron, 2017, Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of Cathepsin S, Front. Immunol., 8, 806, 10.3389/fimmu.2017.00806 Oberhuber, 2016, Impaired endothelial nitric oxide synthase homodimer formation triggers development of transplant vasculopathy - insights from a murine aortic transplantation model, Sci. Rep., 6, 37917, 10.1038/srep37917 Bankhead, 2017, QuPath: open source software for digital pathology image analysis, Sci. Rep., 7, 16878, 10.1038/s41598-017-17204-5 Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat. Methods, 9, 676, 10.1038/nmeth.2019 Lemström, 2004, Role of angiogenic growth factors in transplant coronary artery disease, Ann. Med., 36, 184, 10.1080/07853890310025243 Christie, 2011, The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report--2011, J. Heart Lung Transplant., 30, 1104, 10.1016/j.healun.2011.08.004 Mitchell, 2007, Vascular remodeling in transplant vasculopathy, Circ. Res., 100, 967, 10.1161/01.RES.0000261982.76892.09 Shi, 2014, Cathepsin S contributes to macrophage migration via degradation of elastic fibre integrity to facilitate vein graft neointimal hyperplasia, Cardiovasc. Res., 101, 454, 10.1093/cvr/cvt273 Cheng, 2006, Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3, Am. J. Pathol., 168, 685, 10.2353/ajpath.2006.050295 Cheng, 2004, Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries, Am. J. Pathol., 164, 243, 10.1016/S0002-9440(10)63114-8 Nagano, 1997, Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts, J. Clin. Investig., 100, 550, 10.1172/JCI119564 Klaus, 2018, Cathepsin S is associated with degradation of collagen I in abdominal aortic aneurysm, VASA. Zeitschrift fur Gefasskrankheiten, 47, 285, 10.1024/0301-1526/a000701 Qin, 2012, Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice, Cardiovasc. Res., 96, 401, 10.1093/cvr/cvs263 Samokhin, 2010, Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe−/− mice, J. Cardiovasc. Pharmacol., 56, 98, 10.1097/FJC.0b013e3181e23e10 Merola, 2017, Recent advances in allograft vasculopathy, Curr. Opin. Organ Transplant., 22, 1, 10.1097/MOT.0000000000000370 Tellides, 2007, Interferon-gamma axis in graft arteriosclerosis, Circ. Res., 100, 622, 10.1161/01.RES.0000258861.72279.29 Yu, 2011, AIP1 prevents graft arteriosclerosis by inhibiting interferon-γ-dependent smooth muscle cell proliferation and intimal expansion, Circ. Res., 109, 418, 10.1161/CIRCRESAHA.111.248245 Roche, 1990, Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding, Nature, 345, 615, 10.1038/345615a0 Shi, 1999, Cathepsin S required for normal MHC class II peptide loading and germinal center development, Immunity, 10, 197, 10.1016/S1074-7613(00)80020-5 Yang, 2005, Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis, J. Immunol. (Baltimore, Md. 1950), 174, 1729, 10.4049/jimmunol.174.3.1729 Deschamps, 2011, Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma, Am. J. Respir. Cell Mol. Biol., 45, 81, 10.1165/rcmb.2009-0392OC Lei, 2020, Cathepsin S and protease-activated receptor-2 drive alloimmunity and immune regulation in kidney allograft rejection, Front. Cell Dev. Biol., 8, 398, 10.3389/fcell.2020.00398 Kubo, 2018, Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model, Eur. J. Pharmacol., 838, 145, 10.1016/j.ejphar.2018.09.007 Elmariah, 2014, Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist, PLoS One, 9, 10.1371/journal.pone.0099702 Damiano, 1999, Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery, Thromb. Haemost., 81, 808, 10.1055/s-0037-1614574 Jones, 2018, PAR2 (protease-activated receptor 2) deficiency attenuates atherosclerosis in mice, Arterioscler. Thromb. Vasc. Biol., 38, 1271, 10.1161/ATVBAHA.117.310082 Zuo, 2017, Protease-activated receptor-2 deficiency attenuates atherosclerotic lesion progression and instability in apolipoprotein E-deficient mice, Front. Pharmacol., 8, 647, 10.3389/fphar.2017.00647 Johansson, 2005, Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1{beta}, J. Leukoc. Biol., 78, 967, 10.1189/jlb.0704422 Dekita, 2017, Cathepsin S is involved in Th17 differentiation through the upregulation of IL-6 by activating PAR-2 after systemic exposure to lipopolysaccharide from porphyromonas gingivalis, Front. Pharmacol., 8, 470, 10.3389/fphar.2017.00470 Csernok, 2006, Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway, Blood, 107, 4440, 10.1182/blood-2005-05-1875 Ramelli, 2010, Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivo, Immunology, 129, 20, 10.1111/j.1365-2567.2009.03144.x Shi, 1996, Immunologic basis of transplant-associated arteriosclerosis, Proc. Natl. Acad. Sci. U. S. A., 93, 4051, 10.1073/pnas.93.9.4051 Forbes, 1994, Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rat heart allograft model, Transplantation, 57, 1238, 10.1097/00007890-199404270-00017 Allan, 1997, Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy, Ann. Thorac. Surg., 64, 1019, 10.1016/S0003-4975(97)00796-0 Schnickel, 2004, CD8 lymphocytes are sufficient for the development of chronic rejection, Transplantation, 78, 1634, 10.1097/01.TP.0000141362.33931.40 Fischbein, 2002, Role of CD8+ lymphocytes in chronic rejection of transplanted hearts, J. Thorac. Cardiovasc. Surg., 123, 803, 10.1067/mtc.2002.120008 Rothmeier, 2012, Protease-activated receptor 2 signaling in inflammation, Semin. Immunopathol., 34, 133, 10.1007/s00281-011-0289-1